Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL357203 | 1.00 | ATM (0.47) | ATMTDP1VCAM1METTSHR | |
| SCHEMBL1570007 | 0.88 | ITGB1 (0.53) | VCAM1METTSHRNPSR1HPGD | |
| SCHEMBL11247732 | 0.86 | CASP6 (0.57) | VCAM1METTSHRNPSR1HPGD | |
| SCHEMBL25484994 | 0.84 | GPR35 (0.47) | VCAM1METTSHRNPSR1HPGD | |
| SCHEMBL1027488 | 0.84 | TSHR (0.62) | VCAM1TSHRALDH1A1MAPTNPC1 | |
| SCHEMBL557153 | 0.84 | VCAM1 (0.46) | ATMTDP1VCAM1METTSHR | |
| SCHEMBL29556186 | 0.83 | VCAM1 (0.58) | ATMTDP1VCAM1NPSR1HPGD | |
| SCHEMBL5934 | 0.83 | VCAM1 (0.58) | ATMTDP1VCAM1NPSR1HPGD | |
| SCHEMBL15292815 | 0.82 | VCAM1 (0.45) | VCAM1METTSHRNPSR1HPGD | |
| SCHEMBL28824450 | 0.81 | ATM (0.41) | ATMTDP1VCAM1METTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257052-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12319669-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2025-06-03 | — | — | US | disclosed |
| EP-4405359-A2 | MDM2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| US-20240034725-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2024-02-01 | — | — | US | disclosed |
| EP-4271672-A1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-11802121-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230124938-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2023-04-20 | — | — | US | disclosed |
| WO-2023049790-A2 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| EP-3555064-B9 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2023-03-01 | — | — | EP | disclosed |
| US-11512070-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2022-11-29 | — | — | US | disclosed |
| EP-3555064-B1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2022-11-23 | — | — | EP | disclosed |
| WO-2022225941-A1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11512070-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | ATM 4254/4885TDP1 3756/4885VCAM1 1375/4885 |
| US-20250257052-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | ATM 4254/4885TDP1 3756/4885VCAM1 1375/4885 |
| US-12319669-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | ATM 4254/4885TDP1 3756/4885VCAM1 1375/4885 |
| US-11802121-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | ATM 4254/4885TDP1 3756/4885VCAM1 1375/4885 |
| US-20240034725-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | ATM 4254/4885TDP1 3756/4885VCAM1 1375/4885 |
| US-20230124938-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | ATM 4254/4885TDP1 3756/4885VCAM1 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.